Overview

Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes

Status:
ENROLLING_BY_INVITATION

Trial end date:
2028-07-10

Target enrollment:

Participant gender:

Summary

Glucocorticoids are commonly used in the treatment of autoimmune, inflammatory, and neoplastic diseases. Despite their therapeutic efficacy, they are associated with significant metabolic side effects. In the proposed research, the aim is to assess the metabolic efficacy and safety of fixed-ratio combination therapy (basal insulin + GLP-1 receptor agonist) compared to standard insulin therapy in patients with SID. In a selected group of patients, a randomised clinical trial would be conducted to assess the potential benefits of GLP-1 receptor agonists in the management of SID.

Phase:

PHASE4

Details

Lead Sponsor:

Medical University of Warsaw

Treatments:

Glucagon-Like Peptide 1
Insulin Glargine
lixisenatide